Lates News

date
17/04/2026
According to AI Express, Open Source Securities released a research report on April 17th, giving Guobang Medicine (605507.SH) a "buy" rating. The main reasons for the rating include: 1) a steady growth in performance in the first quarter of 2026, with the cycle of animal medicine raw materials reaching a turning point; 2) optimization of business structure in 2025, with rapid growth in animal medicine products; 3) rich achievements in company registration and high research and development intensity. (Daily Economic News)
Latest
See all latestmore